In This Article:
Hydration Pharmaceuticals (ASX:HPC) Full Year 2024 Results
Key Financial Results
-
Revenue: US$3.20m (down 68% from FY 2023).
-
Net loss: US$5.67m (loss narrowed by 30% from FY 2023).
-
US$0.021 loss per share (improved from US$0.042 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Hydration Pharmaceuticals shares are up 25% from a week ago.
Risk Analysis
You still need to take note of risks, for example - Hydration Pharmaceuticals has 5 warning signs (and 4 which are concerning) we think you should know about.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.